Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology - United States
doi 10.1001/jamadermatol.2020.0723
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2005English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

British Journal of Dermatology
DermatologyMedicine
2018English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2018English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Lack of Effect of 12-Week Treatment With Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients With Moderate to Severe Chronic Plaque Psoriasis

Clinical Pharmacokinetics
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy